Business Context and Reporting Period
This Form 8-K is filed by AmerisourceBergen Corporation (now Cencora, Inc.) on October 24, 2011. The report addresses a preliminary civil settlement agreement regarding pending litigation involving two business units: International Nephrology Network (INN) and ASD Specialty Healthcare, Inc.
Key Financial Metrics
- Settlement Charge: Approximately $16 million.
- Timing of Charge: Recorded in the fourth quarter and full year ended September 30, 2011.
- Impact on Prior Guidance: The charge was not included in the previously announced fiscal year 2011 diluted earnings per share (EPS) guidance range of $2.52 to $2.56.
- Liquidity and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the settlement charge.
Material Changes
The primary material change is the agreement to settle qui tam litigation brought by a former Amgen Inc. employee on behalf of the United States and certain states. The settlement involves claims against INN and ASD but does not require the units to admit liability. The $16 million charge represents a new expense not anticipated in prior fiscal year 2011 earnings expectations.
Outlook, Risks, and Management Commentary
- Settlement Status: The agreement is preliminary and subject to the completion and approval of an executed written settlement agreement, expected to be finalized in fiscal year 2012.
- Liability Admission: The Company does not expect INN or ASD to admit any liability.
- Guidance Impact: Management notes that the $16 million charge falls outside the assumptions used for the previously issued EPS guidance.
- Risks: The filing highlights the resolution of a significant legal contingency involving federal and state false claims acts.
Investor Verification Checklist
- Verify the final execution of the written settlement agreement expected in fiscal year 2012.
- Confirm the exact timing and accounting treatment of the $16 million charge in the Q4 2011 financial statements.
- Assess the impact of the $16 million charge on the revised full-year 2011 diluted EPS, given it was excluded from the $2.52-$2.56 guidance range.
- Monitor for any additional disclosures regarding the qui tam litigation or related regulatory investigations.